Lite Strategy (LITS) EBIT Margin Growth (3y) (2019 - 2023)
Powered by 
Analysis
Lite Strategy (LITS) EBIT Margin Growth (3y) (2019 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -347.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -15,844.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -377.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -204.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7,045.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1,934.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 9,003.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,825.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -2.41 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 27,722.00 |
| Jun 30, 2023 | -80,547.00 |
| Mar 31, 2023 | 72,214.00 |
| Dec 31, 2022 | 122,856.00 |
| Sep 30, 2022 | 88,232.00 |
| Jun 30, 2022 | 89,867.00 |
| Mar 31, 2022 | 78,770.00 |
| Dec 31, 2021 | 42,927.00 |
| Sep 30, 2021 | 179,676.00 |
| Jun 30, 2021 | 115,609.00 |
| Mar 31, 2021 | 119,597.00 |
| Dec 31, 2020 | 159,879.00 |
| Sep 30, 2020 | 294,772.00 |
| Jun 30, 2020 | 103,342.00 |
| Mar 31, 2020 | -98,537.00 |
| Dec 31, 2019 | -126,999.00 |
| Sep 30, 2019 | -69,649.00 |